Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duomeisu (pegylated liposomal doxorubicin) for relapsed or refractory ovarian cancer
ChiCTR1900022962Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Duomeisu in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Peking Union Medical College Hospital. Primary endpoint: progression-free survival. Started Jan 2017; status: recruiting.
02
Drugs
Duomeisu
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR1900022962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022962.